CANBRIDGE PHARM.DL-00001 Total Liabilities
CANBRIDGE PHARM.DL-00001 total liabilities. Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) has total liabilities worth €507.15 Million EUR (≈ $592.91 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of CANBRIDGE PHARM.DL-00001 to measure how many days the company can operate on defensive assets alone.
Total Liabilities of CANBRIDGE PHARM.DL-00001 (2021–2025)
Total liabilities of CANBRIDGE PHARM.DL-00001 from 2021 to 2025. This chart illustrates how CANBRIDGE PHARM.DL-00001's total liabilities have evolved over time, based on quarterly financial data.
CANBRIDGE PHARM.DL-00001 Competitors by Total Liabilities
The table below lists competitors of CANBRIDGE PHARM.DL-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nkarta Inc
NASDAQ:NKTX
|
USA | $89.91 Million |
|
AMREP Corporation
NYSE:AXR
|
USA | $6.61 Million |
|
Idsud S.A
PA:ALIDS
|
France | €8.95 Million |
|
Boldt S.A
BA:BOLT
|
Argentina | AR$60.83 Billion |
|
Alterity Therapeutics Ltd
AU:ATH
|
Australia | AU$2.65 Million |
|
Riber S.A
PA:ALRIB
|
France | €27.29 Million |
|
Balwin Properties Ltd
JSE:BWN
|
South Africa | ZAC3.86 Billion |
|
Yen Sun Technology
TWO:6275
|
Taiwan | NT$2.13 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down CANBRIDGE PHARM.DL-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CANBRIDGE PHARM.DL-00001 (MF1) total assets.
Liquidity & Leverage Metrics
CANBRIDGE PHARM.DL-00001 Total Liabilities Ratios Explained
CANBRIDGE PHARM.DL-00001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CANBRIDGE PHARM.DL-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the annual total liabilities of CANBRIDGE PHARM.DL-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €507.15 Million ≈ $592.91 Million |
-14.23% |
| 2024-12-31 | €591.30 Million ≈ $691.29 Million |
+35.88% |
| 2023-12-31 | €435.15 Million ≈ $508.74 Million |
+10.59% |
| 2022-12-31 | €393.49 Million ≈ $460.03 Million |
+97.60% |
| 2021-12-31 | €199.13 Million ≈ $232.81 Million |
-- |
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more